Sanofi Reports 1Q19 Orthobiologic Revenue of €68MM, Flat vs. 1Q18

by Mike Evers on April 26, 2019

Sanofi’s hyaluronic acid product lines, Synvisc and Synvisc-One, posted revenue of USD $76.4.1MM in 1Q19, flat vs. 1Q18.

U.S. revenue loss diminished from 2018, -2.2% vs. 1Q18
Emerging markets were strong, with +15.4% revenue vs. last year

Synvisc and Synvisc-One sales on an as-reported basis are as follows...

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.

Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.

	1Q19	1Q18	% Chg	% Chg
Orthobiologics	$76.4	$76.4	$0.0	0.0%

Geographic Region	1Q19	1Q18	% Chg	% Chg
US	$49.4	$50.6	-$1.1	-2.2%
Ex-US	$27.0	$25.8	$1.1	4.3%
Europe	$6.7	$6.7	$0.0	0.0%
Emerging Markets	$16.9	$14.6	$2.2	15.4%
Rest of World	$3.4	$4.5	-$1.1	-25.0%
Total	$76.4	$76.4	$0.0	0.0%

	1Q19	1Q18	% Chg	% Chg
Orthobiologics	$76.4	$76.4	$0.0	0.0%

Geographic Region	1Q19	1Q18	% Chg	% Chg
US	$49.4	$50.6	-$1.1	-2.2%
Ex-US	$27.0	$25.8	$1.1	4.3%
Europe	$6.7	$6.7	$0.0	0.0%
Emerging Markets	$16.9	$14.6	$2.2	15.4%
Rest of World	$3.4	$4.5	-$1.1	-25.0%
Total	$76.4	$76.4	$0.0	0.0%

Sanofi Reports 1Q19 Orthobiologic Revenue of €68MM, Flat vs. 1Q18

DePuy Synthes Sees Better Execution and Margins in First Quarter

Orthopedics’ Top Tier to Expand in 2024

Miach Orthopaedics Raises $20 Million in Series B Extension

10 Orthopedic Companies Close New Funding Rounds in 1Q24

Carlsmed Raises Series C to Support aprevo

Get the ORTHOWORLD Newsletter!

Contact Us